Skip Navigation LinksHome > February 19, 2007 - Volume 21 - Issue 4 > Efficacy and safety of TMC114/ritonavir in treatment-experie...
Text sizing:
A
A
A
AIDS:
doi: 10.1097/QAD.0b013e328013d9d7
Fast Track

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

Katlama, Christinea; Esposito, Robertob; Gatell, Jose Mc; Goffard, Jean-Christophed; Grinsztejn, Beatrize; Pozniak, Antonf; Rockstroh, Jurgeng; Stoehr, Albrechth; Vetter, Norberti; Yeni, Patrickj; Parys, Wimk; Vangeneugden, Tonyk; on behalf of the POWER 1 study group

Free Access
Article Outline
Collapse Box

Author Information

From the aHôpital Pitié-Salpêtrière, Paris, France

bPoliclinico di Modena, Modena, Italy

cHospital Clinic Universitary, Barcelona, Spain

dHôpital Universitaire Erasme, Brussels, Belgium

eInstituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Brazil

fChelsea and Westminster Hospital, London, UK

gMediz. Universitätsklinik – Immunologische Ambulanz, Bonn, Germany

hIFI-Institut im AK St. Georg, Hamburg, Germany

iOtto-Wagner-Spital, Interne Lungenabteilung, Vienna, Austria

jHôpital Bichat Paris, Paris, France

kTibotec BVBA, Mechelen, Belgium.

Received 1 September, 2006

Revised 10 October, 2006

Accepted 13 October, 2006

Correspondence to Christine Katlama, Service des Maladies Infectieuses et Tropicales, Hôpital de la Pitié-Salpétrière, 47–83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France. E-mail: christine.katlama@psl.ap-hop-paris.fr

Collapse Box

Abstract

Background: The ongoing phase IIb POWER 1 (TMC114-C213) trial is designed to assess efficacy and safety of the protease inhibitor (PI) TMC114 (darunavir) in treatment-experienced HIV-1-infected patients.

Design: This randomized, partially blinded, 24-week dose-finding study compared efficacy and safety of four doses of TMC114 plus low-dose ritonavir (TMC114/r) with investigator-selected control PI(s) (CPI[s]).

Methods: Patients with one or more primary PI mutation and HIV RNA > 1000 copies/ml received optimized background therapy, plus TMC114/r 400/100 mg once daily, 800/100 mg once daily, 400/100 mg twice daily or 600/100 mg twice daily, or CPI(s). The primary endpoint (intent-to-treat) compared proportions of patients achieving viral load reduction ≥ 1.0 log10 copies/ml from baseline.

Results: In total, 318 patients were treated. Baseline mean viral load was 4.48 log10 copies/ml; median CD4 cell count was 179 cells/μl. In the CPI arm 62% of patients discontinued (virological failure: 54%); 10% of TMC114/r patients discontinued. More TMC114/r (69–77%) than CPI patients (25%) reached the primary endpoint (P < 0.001); 43–53% of TMC114/r patients and 18% of the CPI arm achieved viral load < 50 copies/ml (P < 0.001). TMC114/r demonstrated greater mean CD4 cell count increases versus CPI(s) (68–124 versus 20 cells/μl; P < 0.05). TMC114/r 600/100 mg twice daily demonstrated the highest virological and immunological responses. Adverse event incidence was similar between treatments; headache and diarrhoea were more common with CPI(s).

Conclusions: TMC114/r demonstrated statistically higher 24-week virological response rates and CD4 cell count increases than CPI(s). TMC114/r 600/100 mg twice daily has received regulatory approval in treatment-experienced patients.

Back to Top | Article Outline

Introduction

Protease inhibitors (PIs) have significantly improved the management of HIV infection. However, antiretroviral drug resistance, including multi-drug and cross-resistance, compromises effective long-term therapy. A significant need exists for antiretroviral therapies capable of providing virological suppression, particularly in treatment-experienced HIV patients [1].

The new PI TMC114 (darunavir) is highly active against both wild-type and multi-PI-resistant HIV-1 strains in vitro [2,3] and, in combination with low-dose ritonavir (TMC114/r), demonstrated potent antiviral activity in treatment-experienced patients [4]. TMC114/r 600/100 mg twice daily (b.i.d.) is the recommended dose for treatment-experienced HIV patients.

POWER (Performance Of TMC114/r When evaluated in treatment-Experienced patients with PI Resistance) 1 and 2 (TMC114-C213 and C202) aim to assess the efficacy and safety of TMC114/r versus investigator-selected control PI(s) [CPI(s)] in treatment-experienced patients undergoing virological failure: we report here the pre-planned POWER 1 24-week primary analysis.

Back to Top | Article Outline

Methods

Study design

POWER 1 involves centres in Europe, Australia, Brazil and Canada. The phase IIb 24-week dose-finding phase was randomized, controlled and partially blinded. Prior to randomization, investigators selected an optimized background regimen (OBR) for each patient based on genotypic resistance (VirtualPhenotype; Virco BVBA, Mechelen, Belgium) and treatment history, consisting of two or more nucleoside analogue reverse transcriptase inhibitors (NRTIs; excluding abacavir and investigational NRTIs, except emtricitabine) with or without enfuvirtide. Non-nucleoside analogue reverse transcriptase inhibitors (NNRTIs) were excluded. Patients were stratified by screening viral load (< 20 000 or ≥ 20 000 copies/ml), enfuvirtide use in the OBR and screening primary PI mutation number (1, 2, ≥ 3) [5]. Patients received their OBR plus either CPI(s) (excluding tipranavir and other investigational PIs; atazanavir and fosamprenavir were allowed) (CPI arm), or TMC114/r 400/100 mg once daily (q.d.), 800/100 mg q.d., 400/100 mg b.i.d. or 600/100 mg b.i.d. (blinded for dose not schedule). After the primary analysis cut-off date (1 February 2005), all TMC114/r patients switched to TMC114/r 600/100 mg b.i.d.

OBR and/or CPI(s) alterations were prohibited except for tolerability/toxicity reasons. CPI patients experiencing virological failure (viral load reduction < 0.5 log10 copies/ml from baseline beyond week 12) could ‘roll-over’ to another TMC114/r study.

Discussion with the regulatory authorities led to an amendment of the 24-week primary objective, from evaluation of the dose–response relationship between the TMC114/r dose groups for viral load change from baseline, to comparison of all TMC114/r treatment groups with the CPI arm based on viral load reduction ≥ 1.0 log10 copies/ml from baseline [time-to-loss of virological response (TLOVR) algorithm]. Secondary endpoints included the proportions of patients achieving viral loads < 400 and < 50 copies/ml, viral load and CD4 cell count changes, dose-response, and safety/tolerability.

Viral load was determined using the Roche (Basel, Switzerland) Amplicor HIV-1 monitor. Immunological change was evaluated by absolute and percentage CD4 cell counts. Viral phenotypic (Antivirogram; Virco BVBA, Mechelen, Belgium) and genotypic (VirtualPhenotype Virco BVBA) resistance was determined at screening, days –14 and 1, week 2 and the week 24 or withdrawal visit. Phenotypic data were unavailable at baseline and not used in OBR selection. Adverse events (AEs) and laboratory abnormalities were assessed by clinical evaluations and standard laboratory tests (weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24) and graded according to a modified AIDS Clinical Trial Group (ACTG) severity grading list [6].

The study protocol was reviewed and approved by the appropriate institutional ethics committees and health authorities, and conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.

Back to Top | Article Outline
Study participants

Patients were HIV-infected adults with prior use of two or more NRTIs for at least 3 months, one or more NNRTI in a failing regimen, and one or more PI for at least 3 months (prior enfuvirtide use was allowed), with plasma HIV RNA > 1000 copies/ml and one or more primary PI mutation [5], receiving a stable PI-containing regimen. The proportion of patients with three or more primary PI mutations was limited to 30%.

Exclusion criteria included any currently active AIDS-defining illness, treatment-interruption schedule use at screening, screening investigational antiretroviral use, previous randomization to TMC114 treatment, active liver disease, liver impairment/dysfunction, and acute hepatitis A. Hepatitis B or C co-infected patients were included if their condition was clinically stable and would not require treatment during the study.

Back to Top | Article Outline
Statistical analysis

The primary efficacy and safety analysis was intent-to-treat (ITT; missing or non-completion equals failure). Immunological change was analysed by last observation carried forward (LOCF). Overall significance was adjusted using the Bonferroni–Holms multiple testing procedure [7] to account for multiple comparisons versus the CPI arm after amending the primary efficacy objective. Statistical analyses were adjusted for the stratification factors. To detect a difference of ≥ 0.5 log10 copies/ml in 24-week viral load between the highest and lowest TMC114/r dose groups (common standard deviation of 1) with 80% power at a significance level of 5% (one-sided), 51 patients were required per treatment group. To account for the effect of dropouts on the primary parameters, 60 patients per group were required for the ITT analysis. The same model was applied to compare secondary endpoints between TMC114/r groups and the CPI arm. All analyses were executed as per the pre-planned statistical analysis plan.

Back to Top | Article Outline

Results

Baseline disease characteristics

Demographics and baseline disease characteristics were similar between treatment arms (Table 1); 31% had three or more primary PI mutations [5], which increased to 58% after the IAS-USA guidelines update [8]. Baseline median numbers of primary PI and PI resistance-associated mutations were three and eight, respectively. In total, 11% of patients had previously used enfuvirtide. Overall, 193 (63%) patients were resistant to all commercially available PIs, 52 (17%) were sensitive to one PI, and 63 (20%) were sensitive to two or more PIs. The median baseline TMC114 fold-change (FC) in 50% effective concentration was 3.5; for CPIs and the median FC was > 10 (range, 13.4–230.2).

Table 1
Table 1
Image Tools

The PIs used in the CPI arm were lopinavir (46%), saquinavir (38%), (fos)amprenavir (25%), atazanavir (21%) and indinavir (2%); 68% of PI regimens were single-boosted and 29% were double-boosted with ritonavir.

Back to Top | Article Outline
Patient disposition

Of 697 patients screened, 318 (255 TMC114/r and 63 CPI) were randomized, treated and included in the analysis; the majority of the 363 screened patients who were not randomized either did not meet the eligibility criteria (224), or exceeded the 30% limit for three or more primary PI mutations (107). Sixteen randomized patients were not included (not treated mainly due to withdrawal of consent).

As per protocol, the primary efficacy analysis was performed when the last of 300 patients reached week 24. By the analysis cut-off date, 301 of the 318 randomized and treated patients had reached week 24 or discontinued; 17 had not reached week 24 and were not included in the analysis but censored at their last visit at which viral load data was available (one patient at week 12; three at week 16; 13 at week 20). Overall, 64 patients (20%) discontinued: 25 (10%) and 39 (62%) TMC114/r and CPI patients, respectively, resulting in considerable treatment exposure decreases in the CPI arm versus the TMC114/r groups. Discontinuations in the CPI arm were mainly due to virological failure [34 patients (54%) versus 11 TMC114/r patients (4%)].

Back to Top | Article Outline
Efficacy

The primary efficacy endpoint (viral load reduction ≥ 1.0 log10 copies/ml from baseline) was achieved by 46 (77%), 42 (69%), 43 (72%) and 42 (70%) patients receiving TMC114/r 600/100 mg b.i.d., 400/100 mg b.i.d., 800/100 mg q.d. and 400/100 mg q.d., respectively, compared with 15 (25%) patients receiving CPI(s) (P < 0.001; Fig. 1a).

Fig. 1
Fig. 1
Image Tools

Viral loads < 400 and < 50 copies/ml (Fig. 1b) were achieved by 40 (67%) and 32 (53%) TMC114/r 600/100 mg b.i.d. patients, 42 (69%) and 30 (49%) 400/100 mg b.i.d. patients, 37 (62%) and 29 (48%) 800/100 mg q.d. patients, and 38 (63%) and 26 (43%) 400/100 mg q.d. patients, compared with 15 (25%) and 11 (18%) CPI patients, respectively [P < 0.001 for TMC114/r versus CPI(s)]. Mean viral load reductions from baseline were 2.03, 1.69, 1.83 and 1.78 log10 copies/ml in the TMC114/r 600/100 mg b.i.d., 400/100 mg b.i.d., 800/100 mg q.d., and 400/100 mg q.d. groups, respectively, compared with 0.63 log10 copies/ml in the CPI arm (P < 0.001).

Responses were higher with TMC114/r than CPI(s) across the stratification factors and baseline TMC114 FC (Table 2), although the relatively small patient numbers in these subgroups did not provide sufficient power for conclusive statistical analyses. Across the groups, 19–26 TMC114/r and 18 CPI patients received enfuvirtide for the first time (naive), with 76 to 84% and 39% of patients, respectively, achieving the primary efficacy endpoint (Table 2). Baseline TMC114 FC was the most predictive prognostic factor (P < 0.0001) in a multivariate analysis of covariance on viral load change from baseline at week 24.

Table 2
Table 2
Image Tools

Mean CD4 cell count increases from baseline at week 24 (LOCF) were 124 (P < 0.001), 71, 75 and 68 cells/μl (P < 0.05) for the TMC114/r 600/100 mg b.i.d., 400/100 mg b.i.d., 800/100 mg q.d. and 400/100 mg q.d. groups, respectively, versus 20 cells/μl in the CPI arm (Fig. 2). CD4 change from baseline in the 600/100 mg b.i.d. group was statistically significantly higher than those observed in the 400/100 mg q.d. (P = 0.006), 800/100 mg q.d. (P = 0.009) and 400/100 mg b.i.d. (P = 0.014) groups (pairwise comparisons). At baseline and week 24, 40% (n = 26) and 72% (n = 43), respectively, of TMC114/r 600/100 mg b.i.d. patients had CD4 cell counts above 200 cells/μl, compared with 49% (n = 31) and 58% (n = 5), respectively, of CPI patients.

Fig. 2
Fig. 2
Image Tools
Back to Top | Article Outline
Safety

The safety analysis included patients who received at least one study medication dose, with treatment-emergent safety data recorded between the first intake and either 2 days after the final intake or at the cut-off date. Overall AE incidences (all grades, regardless of causality), were comparable between patients receiving TMC114/r and CPI(s), despite treatment exposure differences (39.8 and 26.3 weeks, respectively). No relationship between TMC114/r dose and AE incidence or discontinuation was observed. Excluding enfuvirtide-associated injection site reactions, the two most common treatment-emergent AEs (≥ 5% of TMC114/r patients) were headache [17%; 24% with CPI(s)] and diarrhoea [16%; 29% with CPI(s)]. Table 3 shows grade 3 or 4 AEs with incidences ≥ 2% in at least one treatment group (regardless of causality). Overall, 36 TMC114/r patients and nine CPI patients (14% each) reported one or more serious AE, most commonly pneumonia and headache. AEs led to discontinuation in 12 (5%) TMC114/r patients and four (6%) CPI patients.

Table 3
Table 3
Image Tools

Changes from baseline in most laboratory parameters were comparable across treatment groups. Grade 3–4 triglyceride increases occurred in 7 and 8% of TMC114/r and CPI patients, respectively; grade 3 total cholesterol increases occurred in 4 and 0% of TMC114/r and CPI patients, respectively. Grade 3–4 increases occurred in 1 and 3% of TMC114/r and CPI patients, respectively, for alanine aminotransferase (ALT), and 0.4 and 5% of TMC114/r and CPI patients, respectively, for aspartate aminotransferase (AST). No grade 4 cholesterol, ALT or AST elevations occurred in TMC114/r patients. AE incidences for hepatitis B or C co-infected patients were similar to those of the overall population.

Three (1%) patients receiving TMC114/r died during the study. One patient (2%) in the CPI arm died 2 weeks after the last follow-up visit. The deaths were considered by the investigators to be unrelated to study medication (supported by the Data and Safety Monitoring Board).

The study has been extended from 96 to 144 weeks, with ongoing collection of safety data.

Back to Top | Article Outline
Long-term results

Updated analyses have been performed following the per-protocol 24-week primary analysis. Data from 65 patients who have received TMC114/r 600/100 mg b.i.d. plus OBR from baseline indicate that efficacy is sustained and remains higher than responses observed with CPI(s) to at least week 48, with 47 (72%) patients achieving the primary parameter and 37 (57%) reaching viral loads < 50 copies/ml, compared with 14 (22%) and nine (14%) of 63 CPI patients, respectively. No new or unforeseen safety issues with TMC114/r treatment were identified (mean treatment exposure 71 weeks).

Back to Top | Article Outline

Discussion

After 24 weeks, TMC114/r led to viral load reductions ≥ 1.0 log10 copies/ml in a significantly higher proportion of treatment-experienced HIV patients than CPI(s). Although this has classically been the efficacy benchmark in treatment-experienced patients, the therapeutic goal for this patient population has been redefined as achieving a viral load < 50 copies/ml [9], which is associated with durability of response [10]. This represents perhaps the most stringent measure of virological efficacy, particularly in treatment-experienced patients. In this context, the efficacy of TMC114/r has been demonstrated by 53% of patients receiving TMC114/r 600/100 mg b.i.d. achieving viral loads < 50 copies/ml after 24 weeks, compared with 18% of patients receiving CPI(s). Patients receiving TMC114/r 600/100 mg b.i.d. also had the highest increase in CD4 cell count and increase in the proportion of patients with CD4 cell counts above 200 cells/μl.

AE incidences were comparable between TMC114/r and CPI(s) (except for diarrhoea and headache, which were lower in the TMC114/r groups), with no observed differences in hepatitis B or C co-infected patients, or relationship between TMC114/r dose and AE incidence.

The limitations of this study include the small number of patients receiving the TMC114/r 600/100 mg b.i.d. dose; however, 255 patients were treated with TMC114/r over 24 weeks and all doses demonstrated improved efficacy over CPIs. In addition, similar results were also observed at this dose in the POWER 2 study [11], supporting the selection of the 600/100 mg b.i.d. dose. Despite initial selection of a population where approximately 70% had two or fewer primary PI mutations, the proportion of patients with three or more mutations increased from 31 to 58% after the IAS-USA guidelines update [8] and therefore represents an advanced population. While this paper is limited to reporting 24-week data, this was the per-protocol time of the primary analysis, consistent with guidelines for this patient population.

TMC114/r demonstrated statistically higher virological and immunological responses compared with CPI(s) at 24 weeks. While pairwise comparisons of TMC114/r doses revealed no statistically significant differences for virological response, numerically the greatest responses were observed with TMC114/r 600/100 mg b.i.d. which, combined with its safety and tolerability profile, supported its recent regulatory approval [12]. All patients receiving TMC114/r have been switched to this recommended dose for the ongoing open-label phase of the trial. Ongoing studies will define the efficacy and safety of TMC114/r in other patient populations.

Back to Top | Article Outline

Acknowledgments

We would like to thank the patients and their families for their participation and support during this study. Special thanks go to Koen De Backer, Marie-Pierre de Béthune, Sandra De Meyer, Martine De Pauw, Frederic Godderis, Richard Hoetelmans, Jasmine Kestemont, Eric Lefebvre, Monika Peters, Vanitha Sekar, Sabrina Spinosa-Guzman, Paul Stoffels, Ben Van Baelem, Hilde Walgraeve and the TMC114 study team for their contributions. The authors would also like to acknowledge Gardiner-Caldwell Communications, for assistance in outline preparation and collating author contributions. Financial assistance to support this service was provided by Tibotec.

Potential conflict of interest and financial disclosures: P.Y. has received study grants and advisory honoraria from Tibotec. C.K. has had associations with Gilead, Roche, GlaxoSmithKline, Tibotec, Bristol Myers Squibb and Boehringer Ingelheim. B.G. has received lecture fees from Bristol Myers Squibb and Tibotec. J.M.G. has received study grants, advisory honoraria or honoraria for lectures from Gilead, Roche, GlaxoSmithKline, Tibotec, Bristol Myers Squibb, Abbott, Pfizer and Boehringer Ingelheim. R.E., A.S., J.-C.G., A.P., J.R. and N.V. all have no contractual obligations, restrictions or conflicts of interest to disclose. W.P. and T.V. are current employees of Tibotec. All authors have reviewed and approved the final draft of the manuscript.

Sponsorship: Tibotec provided funding for the study and their employees collected the data.

Back to Top | Article Outline
Study contributors

In addition to the authors, the POWER 1 study group included the following investigators and contributors to the design, conduct and analysis of the study.

Australia: D. Cooper, J. Hoy, P. Martinez and C. Workman; Austria: A. Rieger; Belgium: N. Clumeck, C-M. Farber and F. van Wanzeele; Brazil: C.A. Da Cunha, R. Pedro, F. de Queiroz Telles, A. Timerman and J. Valdez-Madruga; Canada: P. Junod, D. Kilby, J. McLeod, R. O'Brien, A. Rachlis, C Tsoukas and S. Walmsely; France: J-F. Delfraissy, P-M. Girard, A. Lafeuillade, J-M. Molina, F. Raffi, J. Reynes, W. Rozenbaum and D. Vittecoq; Germany: K. Arasteh, H. Carls, S. Esser, H. Jaeger, J-A. Rump, C. K. Schewe, D. Schuster, S. Staszewski and A. Woehrmann; Hungary: D. Bánhegyi; Italy: A. Lazzarin, F. Mazzotta and V. Vullo; Poland: A. Boron-Kaczmarska; Portugal: T. Branco, R. Sarmento-e-Castro and J. Vera; Spain: K. Auirrebengoa, B. Clotet, J. Gonzalez-Lahoz, J. Iribarren, H. Knobel, M. J. Perez-Elias, J. J. Picazo and I. Santos; Switzerland: E. Bernasconi and M. Opravil; UK: C. Leen and E. Wilkins.

Back to Top | Article Outline

References

1. Gulick RM. New antiretroviral drugs. Clin Microbiol Infect 2003; 9:186–193.

2. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314–2321.

3. Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47:3123–3129.

4. Arastéh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial. AIDS 2005; 19:943–947.

5. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al. Drug resistance mutations in HIV-1 (IAS-USA). Top HIV Med 2003; 11:92–96.

6. AIDS Clinical Trials Group. Division of AIDS table for grading severity of adult adverse experiences. Available from: http://rcc.tech-res-intl.com/DAIDS%20RCC%20Forms/TB_ToxicityTables_Adult_TRP_v01a.pdf 1992 [Accessed: 17 December 2004].

7. Bauer P. Multiple testing in clinical trials. Stat Med 1991; 10:871–890.

8. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004; 12:119–124.

9. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827–843.

10. U.S. Department of Health and Human Services (DHHS) 2005 Guidelines. Available from: http://AIDSinfo.nih.gov [Accessed: 6 October 2005].

11. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: POWER 2. 2006; submitted in parallel to AIDS.

12. Tibotec Inc. PREZISTA™ (darunavir) Prescribing Information. June 2006 [cited September 11 2006]. Available from: http://www.tibotectherapeutics.com/pi.jsp [Accessed: 11 September 2006].

Cited By:

This article has been cited 76 time(s).

Protein & Cell
Closing the door to human immunodeficiency virus
Kang, YX; Guo, J; Chen, ZW
Protein & Cell, 4(2): 86-102.
10.1007/s13238-012-2111-9
CrossRef
Journal of Liquid Chromatography & Related Technologies
Hptlc Method for Determination of Darunavir in Rat Plasma and Its Application in Pharmacokinetic Studies
Ramesh, B; Ramakrishna, S; Reddy, RKK; Babu, KH; Sarma, VUM; Devi, PS
Journal of Liquid Chromatography & Related Technologies, 36(2): 167-179.
10.1080/10826076.2011.647194
CrossRef
International Journal of Std & AIDS
Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities
Seminari, E; De Silvestri, A; Scudeller, L; Scotti, V; Tinelli, C
International Journal of Std & AIDS, 23(): 837-842.
10.1258/ijsa.2012.012047
CrossRef
AIDS Patient Care and Stds
Efficacy of a Reduced Dose of Darunavir/Ritonavir in a Small Cohort of Antiretroviral-Naive HIV-Infected Patients
Lanzafame, M; Lattuada, E; Rigo, F; Vento, S
AIDS Patient Care and Stds, 27(6): 315-316.
10.1089/apc.2013.0061
CrossRef
Plos One
Virologic Response to Tipranavir-Ritonavir or Darunavir-Ritonavir Based Regimens in Antiretroviral Therapy Experienced HIV-1 Patients: A Meta-Analysis and Meta-Regression of Randomized Controlled Clinical Trials
Berhan, A; Berhan, Y
Plos One, 8(4): -.
10.1371/journal.pone.0060814
CrossRef
Clinical Therapeutics
Darunavir: A nonpeptidic antiretroviral protease inhibitor
Mccoy, C
Clinical Therapeutics, 29(8): 1559-1576.
10.1016/j.clinthera.2007.08.016
CrossRef
Journal of Virology
Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier
Dierynck, I; De Wit, M; Gustin, E; Keuleers, I; Vandersmissen, J; Hallenberger, S; Hertogs, K
Journal of Virology, 81(): 13845-13851.
10.1128/JVI.01184-07
CrossRef
Current Medical Research and Opinion
Experience with darunavir in HIV-infected adults enrolled in a US expanded access program: results from a single center
Gathe, J
Current Medical Research and Opinion, 24(3): 769-773.
10.1185/03007990SX261122
CrossRef
AIDS Reviews
Resilience to resistance of HIV-1 protease inhibitors: Profile of darunavir
Lefebvre, E; Schiffer, CA
AIDS Reviews, 10(3): 131-142.

Expert Review of Anti-Infective Therapy
Trends in the European HIV/AIDS epidemic: a perspective from Italy
Madeddu, G; Rezza, G; Mura, MS
Expert Review of Anti-Infective Therapy, 7(1): 25-36.
10.1586/14787210.7.1.25
CrossRef
Expert Opinion on Pharmacotherapy
HIV protease inhibitors: recent clinical trials and recommendations on use
Fernandez-Montero, JV; Barreiro, P; Soriano, V
Expert Opinion on Pharmacotherapy, 10(): 1615-1629.
10.1517/14656560902980202
CrossRef
Antiviral Therapy
Darunavir: pharmacokinetics and drug interactions
Back, D; Sekar, V; Hoetelmans, RMW
Antiviral Therapy, 13(1): 1-13.

Hiv Medicine
Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers
Tomaka, F; Lefebvre, E; Sekar, V; Van Baelen, B; Vangeneugden, T; Vandevoorde, A; Miralles, GD
Hiv Medicine, 10(5): 318-327.
10.1111/j.1468-1293.2008.00690.x
CrossRef
Sexual Health
New therapeutic agents in the management of HIV: an overview of darunavir for clinicians
Rotty, J; Hoy, J
Sexual Health, 5(3): 235-241.
10.1071/SH08005
CrossRef
Drugs
Darunavir A Review of its Use in the Management of HIV Infection in Adults
McKeage, K; Perry, CM; Keam, SJ
Drugs, 69(4): 477-503.

Clinical Pharmacokinetics
Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment
Sekar, V; Spinosa-Guzman, S; De Paepe, E; Stevens, T; Tomaka, F; De Pauw, M; Hoetelmans, RMW
Clinical Pharmacokinetics, 49(5): 343-350.

Journal of Antimicrobial Chemotherapy
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir
Masquelier, B; Assoumou, KL; Descamps, D; Bocket, L; Cottalorda, J; Ruffault, A; Marcelin, AG; Morand-Joubert, L; Tamalet, C; Charpentier, C; Peytavin, G; Antoun, Z; Brun-Vezinet, F; Costagliola, D
Journal of Antimicrobial Chemotherapy, 61(6): 1362-1368.
10.1093/jac/dkn127
CrossRef
AIDS
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
Ortiz, R; DeJesus, E; Khanlou, H; Voronin, E; van Lunzen, J; Andrade-Villanueva, J; Fourie, J; De Meyer, S; De Pauw, M; Lefebvre, E; Vangeneugden, T; Spinosa-Guzman, S
AIDS, 22(): 1389-1397.

Antiviral Therapy
Safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection
Gottlieb, M; Thommes, JA
Antiviral Therapy, 13(5): 723-727.

Antiviral Research
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
Wensing, AMJ; van Maarseveen, NM; Nijhuis, M
Antiviral Research, 85(1): 59-74.
10.1016/j.antiviral.2009.10.003
CrossRef
AIDS Reader
Recent highlights in clinical AIDS research
Laurence, J
AIDS Reader, 18(2): 64-66.

Current Hiv Research
Susceptibility of HIV-1 to Tipranavir and Other Antiretroviral Agents in Treatment-Experienced Patients: The UTILIZE Study
Baxter, JD; Bhatti, L; Coakley, E; Bartczak, J; McDonough, M; Vinisko, R; Piliero, PJ
Current Hiv Research, 8(4): 347-354.

Lancet
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial
Madruga, JV; Berger, D; McMurchie, M; Suter, F; Banhegyi, D; Ruxrungtham, K; Norris, D; Lefebvre, E; de Bethune, MP; Tomaka, F; De Pauw, M; Vangeneugden, T; Spinoso-Guzman, S
Lancet, 370(): 49-58.

Antiviral Therapy
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96
Arasteh, K; Yeni, P; Pozniak, A; Grinsztejn, B; Jayaweera, D; Roberts, A; Hoy, J; De Meyer, S; Vangeneugden, T; Tomaka, F
Antiviral Therapy, 14(6): 859-864.
10.3851/IMP1301
CrossRef
Clinical Infectious Diseases
Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive Antiretroviral regimen
Gandhi, T; Nagappan, V; Cinti, S; Wei, W; Kazanjian, P
Clinical Infectious Diseases, 45(8): 1085-1092.
10.1086/521937
CrossRef
Lancet
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
Phillips, AN; Leen, C; Wilson, A; Anderson, J; Dunn, D; Schwenk, A; Orkin, C; Hill, T; Fisher, M; Walsh, J; Pillay, D; Bansi, L; Gazzard, B; Easterbrook, P; Gilson, R; Johnson, M; Sabin, CA
Lancet, 370(): 1923-1928.

Journal of Clinical Pharmacology
Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers
Sekar, VJ; Spinosa-Guzmon, S; De Paepe, E; De Pauw, M; Vangeneugden, T; Lefebvre, E; Hoetelmans, RMW
Journal of Clinical Pharmacology, 48(1): 60-65.
10.1177/091270007309706
CrossRef
Current Opinion in Investigational Drugs
Novel treatment options for pediatric HIV infection
Day, E; Buckberry, K; Sharland, MR; Chakraborty, R
Current Opinion in Investigational Drugs, 9(2): 170-175.

Journal of Infectious Diseases
Managing antiretroviral therapy: Changing regimens, resistance testing, and the risks from structured treatment interruptions
Eron, JJ
Journal of Infectious Diseases, 197(): S261-S271.
10.1086/533418
CrossRef
Journal of Infectious Diseases
Defining HIV susceptibility to new Antiretroviral agents - Darunavir
Haubrich, R
Journal of Infectious Diseases, 196(8): 1125-1127.
10.1086/521631
CrossRef
AIDS
Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir
Chaix, ML; Sahali, S; Pallier, C; Barrail-Tran, A; Delfraissy, JF; Ghosn, J
AIDS, 22(): 2405-2407.

Journal of Medicinal Chemistry
Solution Kinetics Measurements Suggest HIV-1 Protease Has Two Binding Sites for Darunavir and Amprenavir
Kovalevsky, AY; Ghosh, AK; Weber, IT
Journal of Medicinal Chemistry, 51(): 6599-6603.
10.1021/jm800283k
CrossRef
European Journal of Medical Research
Efficacy and Safety of Darunavir and Etravirine in An Antiretroviral Multi-Experienced Youth With Vertically Hiv-1 Infection
Rosso, R; Bernardini, C; Bruzzone, B; Secondo, G; Icardi, G; Viscoli, C; Di Biagio, A
European Journal of Medical Research, 14(3): 136-138.

Hiv Clinical Trials
Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals
Elzi, L; Kaufmann, G; Weber, R; Fux, CA; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Battegay, M
Hiv Clinical Trials, 10(4): 207-214.
10.1310/hct1004-207
CrossRef
Hiv Clinical Trials
Efficacy and Safety of Switching from Enfuvirtide to Raltegravir in Patients with Virological Suppression
Santos, JR; Llibre, JM; Ferrer, E; Domingo, P; Imaz, A; Molto, J; Martin-Iguacel, R; Caum, C; Podzamczer, D; Clotet, B
Hiv Clinical Trials, 10(6): 432-438.
10.1310/hct1006-432
CrossRef
Lancet
Raltegravir: a new anti retroviral class for salvage therapy
Cahn, P; Sued, O
Lancet, 369(): 1235-1236.

AIDS Reader
When and how to use tipranavir and darunavir
Hoffmann, CJ; Gallant, JE
AIDS Reader, 17(4): 194-+.

Hiv Clinical Trials
Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease
Pulido, F; Del Pozo, MA; Fernandez-Guerrero, M; Moreno, A; Oteo, JA; Flores, J; Pedrol, E; Torres, R; Padilla, B; Tellez, MJ; Garcia, J; Gonzalez-Garcia, J
Hiv Clinical Trials, 9(2): 83-90.
10.1310/hct0902-83
CrossRef
Biological & Pharmaceutical Bulletin
The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors
Takahashi, M; Kudaka, Y; Okumura, N; Hirano, A; Banno, K; Kaneda, T
Biological & Pharmaceutical Bulletin, 30(): 1947-1949.

Hiv Clinical Trials
Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naive and -Experienced Patients
Boffito, M; Miralles, D; Hill, A
Hiv Clinical Trials, 9(6): 418-427.
10.1310/hct0906-418
CrossRef
Hiv Clinical Trials
Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3
Rachlis, A; Clotet, B; Baxter, J; Murphy, R; Lefebvre, E
Hiv Clinical Trials, 8(4): 213-220.
10.1310/hct0804-213
CrossRef
Drugs
Darunavir - In the treatment of HIV-1 infection
Fenton, C; Perry, CM
Drugs, 67(): 2791-2801.

Antimicrobial Agents and Chemotherapy
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir
Lambert-Niclot, S; Flandre, P; Canestri, A; Peytavin, G; Blanc, C; Agher, R; Soulie, C; Wirden, M; Katlama, C; Calvez, V; Marcelin, AG
Antimicrobial Agents and Chemotherapy, 52(2): 491-496.
10.1128/AAC.00909-07
CrossRef
Lancet
HIV entry inhibitors
Este, JA; Telenti, A
Lancet, 370(): 81-88.

Rapid Communications in Mass Spectrometry
Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry
ter Heine, R; Aiderden-Los, CG; Rosing, H; Hillebrand, MJX; van Gorp, ECM; Huitema, ADR; Beijnen, JH
Rapid Communications in Mass Spectrometry, 21(): 2505-2514.
10.1002/rcm.3119
CrossRef
New England Journal of Medicine
Raltegravir with optimized background therapy for resistant HIV-1 infection
Steigbigel, RT; Cooper, DA; Kumar, PN; Eron, JE; Schechter, M; Markowitz, M; Loutfy, MR; Lennox, JL; Gatell, JM; Rockstroh, JK; Katlama, C; Yeni, P; Lazzarin, A; Clotet, B; Zhao, J; Chen, J; Ryan, DM; Rhodes, RR; Killar, JA; Gilde, LR; Strohmaier, KM; Meibohm, AR; Miller, MD; Hazuda, DJ; Nessly, ML; DiNubile, MJ; Isaacs, RD; Nguyen, B; Teppler, H
New England Journal of Medicine, 359(4): 339-354.

AIDS Reader
Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: A report of 3 cases
Rawizza, HE; Sax, PE
AIDS Reader, 18(9): 466-+.

International Journal of Infectious Diseases
Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa
Cooper, CL; Mills, E; Wabwire, BO; Ford, N; Olupot-Olupot, P
International Journal of Infectious Diseases, 13(3): 302-306.
10.1016/j.ijid.2008.06.042
CrossRef
International Journal of Pharmaceutics
Dog model with implanted pump to test boosters for antiretroviral medication
Schueller, L; Baert, L; Lachau-Durand, S; Borghys, H; Clessens, E; Van den Mooter, G; Van Gyseghem, E; Jonckers, THM; Van Remoortere, P; Wigerinck, P; Rosier, J
International Journal of Pharmaceutics, 355(): 45-52.
10.1016/j.ijpharm.2007.09.025
CrossRef
Journal of Antimicrobial Chemotherapy
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients
Descamps, D; Lambert-Niclot, S; Marcelin, AG; Peytavin, G; Roquebert, B; Katlama, C; Yeni, P; Felices, M; Calvez, V; Brun-Vezinet, F
Journal of Antimicrobial Chemotherapy, 63(3): 585-592.
10.1093/jac/dkn544
CrossRef
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine
Fayet, A; Beguin, A; Zanolari, B; Cruchon, S; Guignard, N; Telenti, A; Cavassini, M; Gunthard, HF; Buclin, T; Biollaz, J; Rochat, B; Decosterd, LA
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 877(): 1057-1069.
10.1016/j.jchromb.2009.02.057
CrossRef
Lancet
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials
Clotet, B; Bellos, N; Molina, JM; Cooper, D; Goffard, JC; Lazzarin, A; Wohrmann, A; Katlama, C; Wilkin, T; Haubrich, R; Cohen, C; Farthing, C; Jayaweera, D; Markowitz, M; Ruane, P; Spinosa-Guzman, S; Lefebvre, E
Lancet, 369(): 1169-1178.
10.1016/S01406736(07)60497-8
CrossRef
Antiviral Therapy
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers
Scholler-Gyure, M; Kakuda, TN; Sekar, V; Woodfall, B; De Smedt, G; Lefebvre, E; Peeters, M; Hoetelmans, RM
Antiviral Therapy, 12(5): 789-796.

AIDS Reviews
Treatment of heavily antiretroviral-experienced HIV-infected patients
Van Lunzen, J
AIDS Reviews, 9(4): 246-253.

Infections in Medicine
New Advances ion Antiretroviral Therapy
Rathbun, RC; Stephens, JR; Stroup, J
Infections in Medicine, 26(4): 113-120.

Hiv Clinical Trials
The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients
Demeter, LM; Mukherjee, AL; DiFrancesco, R; Jiang, H; DiCenzo, R; Bastow, B; Rinehart, AR; Morse, GD; Albrecht, M
Hiv Clinical Trials, 9(1): 61-72.
10.1310/hct0901-61
CrossRef
AIDS Research and Human Retroviruses
Resistance profile of darunavir: Combined 24-week results from the POWER trials
de Meyer, S; Vangeneugden, T; van Baelen, B; de Paepe, E; van Marck, H; Picchio, G; Lefebvre, E; de Bethune, MP
AIDS Research and Human Retroviruses, 24(3): 379-388.
10.1089/aid.2007.0173
CrossRef
Future Virology
Ritonavir-boosted darunavir: a powerful option for treatment-experienced HIV-1-infected patients
Menendez-Arias, L; Matamoros, T; Alvarez, M
Future Virology, 3(5): 423-434.
10.2217/17460794.3.5.423
CrossRef
AIDS Research and Human Retroviruses
Effect of Baseline Viral Susceptibility on Response to Darunavir/Ritonavir versus Control Protease Inhibitors in Treatment-Experienced HIV Type 1-Infected Patients: POWER 1 and 2
Pozniak, A; Opravil, M; Beatty, G; Hill, A; de Bethune, MP; Lefebvre, E
AIDS Research and Human Retroviruses, 24(): 1275-1280.
10.1089/aid.2007.0275
CrossRef
Current Hiv Research
Clinical Validation and Applicability of Different Tipranavir/Ritonavir Genotypic Scores in HIV-1 Protease Inhibitor-Experienced Patients
Saracino, A; Monno, L; Tartaglia, A; Tinelli, C; Seminari, E; Maggiolo, F; Bonora, S; Rusconi, S; Micheli, V; Lo Caputo, S; Lazzaroni, L; Ferrara, S; Ladisa, N; Nasta, P; Parruti, G; Bellagamba, R; Forbici, F; Angarano, G
Current Hiv Research, 7(4): 425-433.

Clinical Pharmacokinetics
Clinical pharmacokinetics of darunavir
Rittweger, M; Arasteh, K
Clinical Pharmacokinetics, 46(9): 739-756.

Expert Opinion on Pharmacotherapy
Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients
Hull, MW; Montaner, JSG
Expert Opinion on Pharmacotherapy, 11(8): 1433-1437.
10.1517/14656561003724754
CrossRef
Lancet
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
Lazzarin, A; Campbell, T; Clotet, B; Johnson, M; Katlama, C; Moll, A; Towner, W; Trortier, B; Peeters, M; Vingerhoets, J; de Smedt, G; Baeten, B; Beets, G; Sinha, R; Woodfall, B
Lancet, 370(): 39-48.

Expert Opinion on Pharmacotherapy
Darunavir (TMC114): a new HIV-1 protease inhibitor
Molina, JM; Hill, A
Expert Opinion on Pharmacotherapy, 8(): 1951-1964.
10.1517/14656566.8.12.1951
CrossRef
Journal of Infectious Diseases
Prevalence of darunavir resistance-associated mutations: Patterns of occurrence and association with past treatment
Mitsuya, Y; Liu, TF; Rhee, SY; Fessel, WJ; Shafer, RW
Journal of Infectious Diseases, 196(8): 1177-1179.
10.1086/521624
CrossRef
Drugs of Today
Darunavir
El-Atrouni, WI; Temesgen, Z
Drugs of Today, 43(): 671-679.

Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients
D'Avolio, A; Siccardi, M; Sciandra, M; Lorena, B; Bonora, S; Trentini, L; Di Perri, G
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 859(2): 234-240.
10.1016/j.jchromb.2007.10.003
CrossRef
AIDS Reviews
From TMC114 to Darunavir: Five Years of Data on Efficacy
Llibre, JM; Imaz, A; Clotet, B
AIDS Reviews, 15(2): 112-121.

Biomedicine & Pharmacotherapy
Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project)
Menzaghi, B; Ricci, E; Carenzi, L; Parruti, G; Orofino, G; Guastavigna, M; Madeddu, G; Maggi, P; Di Biagio, A; Corsi, P; Penco, G; De Socio, G; Martinelli, C; Vichi, F; Celesia, BM; Franzetti, M; Grosso, C; Molteni, C; Bonfanti, P; Quirino, T
Biomedicine & Pharmacotherapy, 67(4): 293-298.
10.1016/j.biopha.2012.12.005
CrossRef
AIDS
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study
McKinnell, JA; Lin, H; Nevin, CN; Willig, JH; McFarland, G; Genz, M; Raper, JL; DeLaitsch, LL; Mrus, JM; Klaskala, W; Mugavero, MJ; Saag, MS
AIDS, 23(12): 1539-1546.
10.1097/QAD.0b013e32832c7b5c
PDF (134) | CrossRef
AIDS
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
Mills, AM; Nelson, M; Jayaweera, D; Ruxrungtham, K; Cassetti, I; Girard, P; Workman, C; Dierynck, I; Sekar, V; Abeele, CV; Lavreys, L
AIDS, 23(13): 1679-1688.
10.1097/QAD.0b013e32832d7350
PDF (404) | CrossRef
AIDS
Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus
Thuret, I; Chaix, M; Tamalet, C; Reliquet, V; Firtion, G; Tricoire, J; Rabaud, C; Frange, P; Aumaître, H; Blanche, S
AIDS, 23(17): 2364-2366.
10.1097/QAD.0b013e328331a456
PDF (498) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients: 24-Week Results of POWER 3
Molina, J; Cohen, C; Katlama, C; Grinsztejn, B; Timerman, A; Pedro, Rd; Vangeneugden, T; Miralles, D; Meyer, SD; Parys, W; Lefebvre, E; on Behalf of the TMC114-C208 and -C215 Study Groups,
JAIDS Journal of Acquired Immune Deficiency Syndromes, 46(1): 24-31.
10.1097/QAI.0b013e3181359cfb
PDF (131) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Pharmacokinetics of Coadministered Ritonavir-Boosted Elvitegravir and Zidovudine, Didanosine, Stavudine, or Abacavir
Ramanathan, S; Shen, G; Hinkle, J; Enejosa, J; Kearney, BP
JAIDS Journal of Acquired Immune Deficiency Syndromes, 46(2): 160-166.
10.1097/QAI.0b013e318151fd9a
PDF (145) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Efficacy of Once-Daily Darunavir/Ritonavir 800/100 mg in HIV-Infected, Treatment-Experienced Patients With No Baseline Resistance-Associated Mutations to Darunavir
De Meyer, SM; Spinosa-Guzman, S; Vangeneugden, TJ; de Béthune, M; Miralles, GD
JAIDS Journal of Acquired Immune Deficiency Syndromes, 49(2): 179-182.
10.1097/QAI.0b013e318183a959
PDF (92) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Determinants of HIV-1 Genotypic Resistance to Darunavir (TMC114) in a Large Italian Resistance Database (Antiretroviral Resistance Cohort Analysis)
Punzi, G; Zazzi, M; on Behalf of the ARCA Collaborative Group, ; Micheli, V; Meraviglia, P; Trezzi, M; Paolini, E; Giacometti, A; Corsi, P; Pietro, MD; Monno, L; Rusconi, S; Gianotti, N; Adorni, F; Boeri, E; Menzo, S; Gonnelli, A
JAIDS Journal of Acquired Immune Deficiency Syndromes, 46(3): 373-375.
10.1097/QAI.0b013e3181378f73
PDF (244) | CrossRef
Back to Top | Article Outline
Keywords:

HIV; TMC114; darunavir; protease inhibitor; treatment-experienced patients; efficacy; safety

© 2007 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.